Kus, TulayAktas, GokmenOktay, CemilPuyan, Fulya OzTastekin, Ebru2024-06-122024-06-1220220959-49731473-5741https://doi.org/10.1097/CAD.0000000000001272https://hdl.handle.net/20.500.14551/18271Rearrangements of the anaplastic lymphoma kinase (ALK) gene are present in 3-5% of non-small-cell lung cancer (NSCLC), while it was 0.2% in NSCLC tumors. Due to its low frequency, it is extremely challenging to conduct randomized clinical trials of ALK-targeted therapies in NSCLC tumors. In the present case, we describe the first reported case of triple-negative breast cancer (TNBC) harboring the ALK fusion mutation that responded to ALK-targeted therapy after progression with two lines of chemotherapy. Searching for ALK gene rearrangement or other fusion, especially in patients with chemotherapy-resistant TNBC, opens the door to new treatment strategies.en10.1097/CAD.0000000000001272info:eu-repo/semantics/closedAccessAlk FusionBreast CancerCrizotinibTriple-NegativeTreatmentCell Lung-CancerArticle334400405Q3WOS:0007667553000092-s2.0-8512638891235171116Q3